Hookipa Retained Earnings vs Other Liab Analysis

HOOK Stock

USD 2.29 0.14 6.51%

Hookipa Pharma financial indicator trend analysis is much more than just examining Hookipa Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hookipa Pharma is a good investment. Please check the relationship between Hookipa Pharma Retained Earnings and its Other Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Retained Earnings vs Other Liab

Retained Earnings vs Other Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hookipa Pharma Retained Earnings account and Other Liab. At this time, the significance of the direction appears to have pay attention.

The correlation between Hookipa Pharma's Retained Earnings and Other Liab is -0.89. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Other Liab in the same time period over historical financial statements of Hookipa Pharma, assuming nothing else is changed. The correlation between historical values of Hookipa Pharma's Retained Earnings and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Hookipa Pharma are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Retained Earnings i.e., Hookipa Pharma's Retained Earnings and Other Liab go up and down completely randomly.

Correlation Coefficient

-0.89

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Other Liab

Most indicators from Hookipa Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hookipa Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.At this time, Hookipa Pharma's Tax Provision is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 57.8 M this year, although the value of Selling General Administrative will most likely fall to about 15.8 M.

	2021	2022	2023	2024 (projected)
Interest Expense	898K	687K	317K	565.6K
Depreciation And Amortization	4.6M	3.6M	3.6M	2.9M

Interest Expense Depreciation And Amortization

Hookipa Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.83	0.85	0.84	0.93	0.57	0.98	0.86	0.73	-0.94	-0.8	0.74	0.96	0.87	0.72	0.56	-0.58	0.96	0.91	-0.8	-0.56	-0.77	0.94	0.78	0.88	-0.69
Short Long Term Debt Total	0.83		0.71	0.64	0.91	0.19	0.9	0.84	0.43	-0.69	-0.58	0.59	0.74	0.86	0.81	0.56	-0.33	0.74	0.76	-0.71	-0.3	-0.84	0.76	0.85	0.66	-0.84
Other Current Liab	0.85	0.71		0.97	0.82	0.71	0.85	0.92	0.9	-0.68	-0.92	0.82	0.7	0.91	0.62	0.15	-0.83	0.7	0.89	-0.73	-0.81	-0.78	0.97	0.9	0.94	-0.65
Total Current Liabilities	0.84	0.64	0.97		0.82	0.75	0.82	0.85	0.95	-0.69	-0.94	0.9	0.7	0.86	0.68	0.23	-0.8	0.7	0.9	-0.77	-0.79	-0.79	0.95	0.85	0.98	-0.66
Total Stockholder Equity	0.93	0.91	0.82	0.82		0.43	0.93	0.86	0.71	-0.81	-0.72	0.71	0.85	0.88	0.91	0.59	-0.45	0.85	0.83	-0.75	-0.42	-0.95	0.87	0.9	0.83	-0.91
Other Liab	0.57	0.19	0.71	0.75	0.43		0.45	0.5	0.82	-0.6	-0.89	0.61	0.51	0.49	0.25	-0.2	-0.91	0.51	0.58	-0.43	-0.92	-0.38	0.64	0.47	0.71	-0.25
Net Tangible Assets	0.98	0.9	0.85	0.82	0.93	0.45		0.88	0.66	-0.88	-0.75	0.73	0.92	0.89	0.73	0.54	-0.53	0.92	0.89	-0.78	-0.5	-0.8	0.94	0.82	0.84	-0.72
Property Plant And Equipment Net	0.86	0.84	0.92	0.85	0.86	0.5	0.88		0.74	-0.66	-0.79	0.69	0.69	1.0	0.67	0.33	-0.68	0.69	0.92	-0.82	-0.66	-0.8	0.91	0.92	0.85	-0.71
Current Deferred Revenue	0.73	0.43	0.9	0.95	0.71	0.82	0.66	0.74		-0.6	-0.87	0.77	0.6	0.74	0.58	0.1	-0.79	0.6	0.77	-0.62	-0.79	-0.71	0.85	0.76	0.91	-0.57
Net Debt	-0.94	-0.69	-0.68	-0.69	-0.81	-0.6	-0.88	-0.66	-0.6		0.72	-0.6	-0.98	-0.67	-0.6	-0.52	0.51	-0.98	-0.75	0.63	0.48	0.62	-0.8	-0.58	-0.73	0.56
Retained Earnings	-0.8	-0.58	-0.92	-0.94	-0.72	-0.89	-0.75	-0.79	-0.87	0.72		-0.85	-0.67	-0.79	-0.55	-0.08	0.92	-0.67	-0.85	0.73	0.91	0.67	-0.89	-0.76	-0.92	0.54
Accounts Payable	0.74	0.59	0.82	0.9	0.71	0.61	0.73	0.69	0.77	-0.6	-0.85		0.61	0.71	0.67	0.36	-0.64	0.61	0.85	-0.83	-0.65	-0.69	0.86	0.67	0.93	-0.56
Cash	0.96	0.74	0.7	0.7	0.85	0.51	0.92	0.69	0.6	-0.98	-0.67	0.61		0.7	0.62	0.59	-0.44	1.0	0.77	-0.65	-0.41	-0.65	0.83	0.61	0.74	-0.58
Non Current Assets Total	0.87	0.86	0.91	0.86	0.88	0.49	0.89	1.0	0.74	-0.67	-0.79	0.71	0.7		0.72	0.37	-0.66	0.7	0.92	-0.84	-0.63	-0.83	0.91	0.93	0.86	-0.75
Non Currrent Assets Other	0.72	0.81	0.62	0.68	0.91	0.25	0.73	0.67	0.58	-0.6	-0.55	0.67	0.62	0.72		0.66	-0.22	0.62	0.66	-0.69	-0.2	-0.95	0.66	0.8	0.71	-0.96
Other Assets	0.56	0.56	0.15	0.23	0.59	-0.2	0.54	0.33	0.1	-0.52	-0.08	0.36	0.59	0.37	0.66		0.28	0.59	0.47	-0.6	0.28	-0.47	0.36	0.25	0.36	-0.5
Long Term Debt	-0.58	-0.33	-0.83	-0.8	-0.45	-0.91	-0.53	-0.68	-0.79	0.51	0.92	-0.64	-0.44	-0.66	-0.22	0.28		-0.44	-0.68	0.52	1.0	0.41	-0.73	-0.61	-0.74	0.27
Cash And Short Term Investments	0.96	0.74	0.7	0.7	0.85	0.51	0.92	0.69	0.6	-0.98	-0.67	0.61	1.0	0.7	0.62	0.59	-0.44		0.77	-0.65	-0.41	-0.65	0.83	0.61	0.74	-0.58
Net Receivables	0.91	0.76	0.89	0.9	0.83	0.58	0.89	0.92	0.77	-0.75	-0.85	0.85	0.77	0.92	0.66	0.47	-0.68	0.77		-0.95	-0.68	-0.71	0.95	0.78	0.94	-0.6
Common Stock Shares Outstanding	-0.8	-0.71	-0.73	-0.77	-0.75	-0.43	-0.78	-0.82	-0.62	0.63	0.73	-0.83	-0.65	-0.84	-0.69	-0.6	0.52	-0.65	-0.95		0.53	0.66	-0.81	-0.66	-0.86	0.57
Long Term Debt Total	-0.56	-0.3	-0.81	-0.79	-0.42	-0.92	-0.5	-0.66	-0.79	0.48	0.91	-0.65	-0.41	-0.63	-0.2	0.28	1.0	-0.41	-0.68	0.53		0.38	-0.71	-0.58	-0.74	0.24
Non Current Liabilities Total	-0.77	-0.84	-0.78	-0.79	-0.95	-0.38	-0.8	-0.8	-0.71	0.62	0.67	-0.69	-0.65	-0.83	-0.95	-0.47	0.41	-0.65	-0.71	0.66	0.38		-0.77	-0.94	-0.78	0.98
Capital Surpluse	0.94	0.76	0.97	0.95	0.87	0.64	0.94	0.91	0.85	-0.8	-0.89	0.86	0.83	0.91	0.66	0.36	-0.73	0.83	0.95	-0.81	-0.71	-0.77		0.84	0.96	-0.64
Other Current Assets	0.78	0.85	0.9	0.85	0.9	0.47	0.82	0.92	0.76	-0.58	-0.76	0.67	0.61	0.93	0.8	0.25	-0.61	0.61	0.78	-0.66	-0.58	-0.94	0.84		0.81	-0.88
Other Stockholder Equity	0.88	0.66	0.94	0.98	0.83	0.71	0.84	0.85	0.91	-0.73	-0.92	0.93	0.74	0.86	0.71	0.36	-0.74	0.74	0.94	-0.86	-0.74	-0.78	0.96	0.81		-0.64
Total Liab	-0.69	-0.84	-0.65	-0.66	-0.91	-0.25	-0.72	-0.71	-0.57	0.56	0.54	-0.56	-0.58	-0.75	-0.96	-0.5	0.27	-0.58	-0.6	0.57	0.24	0.98	-0.64	-0.88	-0.64

Click cells to compare fundamentals

Hookipa Pharma Account Relationship Matchups

Hookipa Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	143.7M	187.8M	126.0M	170.5M	161.3M	146.4M
Short Long Term Debt Total	10.6M	10.5M	10.6M	6.5M	6.6M	8.3M
Other Current Liab	8.4M	6.4M	11.6M	13.4M	14.4M	9.4M
Total Current Liabilities	14.8M	21.1M	27.7M	35.6M	42.0M	25.1M
Total Stockholder Equity	117.9M	156.1M	89.6M	102.5M	89.9M	87.6M
Other Liab	1.9M	1.9M	2.7M	29.1M	33.4M	35.1M
Net Tangible Assets	117.9M	156.1M	89.6M	102.5M	117.9M	66.6M
Property Plant And Equipment Net	14.6M	14.0M	22.1M	22.0M	13.2M	14.7M
Current Deferred Revenue	3.6M	4.6M	6.2M	16.0M	14.7M	8.4M
Net Debt	(102.6M)	(132.7M)	(56.3M)	(106.9M)	(110.5M)	(116.1M)
Retained Earnings	(103.0M)	(147.1M)	(222.8M)	(287.7M)	(369.3M)	(350.8M)
Accounts Payable	944K	8.0M	8.8M	5.5M	12.5M	6.4M
Cash	113.2M	143.2M	66.9M	113.4M	117.1M	104.3M
Non Current Assets Total	15.7M	16.3M	23.9M	23.3M	14.2M	16.2M
Non Currrent Assets Other	1.1M	1.9M	1.4M	863K	1.0M	1.3M
Other Assets	1.1M	10.1M	1.8M	1.3M	1.0	0.95
Long Term Debt	3.5M	4.5M	2.2M	911K	819.9K	778.9K
Cash And Short Term Investments	113.2M	143.2M	66.9M	113.4M	117.1M	104.3M
Net Receivables	9.7M	20.7M	21.2M	22.0M	19.3M	16.4M
Common Stock Shares Outstanding	17.9M	2.6M	3.3M	6.6M	9.5M	8.3M
Long Term Debt Total	3.9M	4.5M	2.2M	911K	819.9K	778.9K
Liabilities And Stockholders Equity	143.7M	187.8M	126.0M	170.5M	161.3M	146.4M
Non Current Liabilities Total	11.1M	10.6M	8.8M	32.3M	29.5M	24.4M
Capital Surpluse	225.6M	309.3M	317.1M	397.3M	457.0M	230.1M
Other Current Assets	13.3M	8.1M	15.0M	12.7M	10.7M	11.1M
Other Stockholder Equity	81.8M	309.3M	317.1M	397.3M	467.0M	264.5M
Total Liab	25.8M	31.7M	36.5M	67.9M	71.5M	42.7M
Net Invested Capital	122.6M	160.7M	94.6M	105.0M	91.0M	91.7M
Property Plant And Equipment Gross	14.6M	14.0M	28.5M	29.8M	23.0M	18.5M
Total Current Assets	128.0M	171.5M	102.1M	147.2M	147.1M	130.2M
Accumulated Other Comprehensive Income	(4.7M)	(6.1M)	(4.8M)	(7.2M)	(7.9M)	(8.3M)
Non Current Liabilities Other	2.2M	1.4M	2.6M	31.4M	6.0M	8.0M
Net Working Capital	113.3M	150.4M	74.5M	111.6M	105.1M	105.0M
Property Plant Equipment	14.6M	14.0M	16.4M	18.0M	20.7M	13.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:

How To Invest In Hookipa

Details

Is Hookipa Stock a good investment?

Details

What is Hookipa Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.67)

Revenue Per Share

4.403

Quarterly Revenue Growth

(0.52)

Return On Assets

(0.20)

Return On Equity

(0.49)

The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hookipa Retained Earnings vs Other Liab Analysis

Retained Earnings vs Other Liab

Retained Earnings vs Other Liab Correlation Analysis

Correlation Coefficient

Retained Earnings

Other Liab

Hookipa Pharma fundamental ratios Correlations

Hookipa Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hookipa Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt Total	+ 1.0	Long Term Debt
Net Tangible Assets	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.98	Total Current Liabilities
Total Liab	+ 0.98	Non Current Liabilities Total

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Liab	- 0.96	Non Currrent Assets Other
Common Stock Shares Outstanding	- 0.95	Net Receivables
Non Current Liabilities Total	- 0.95	Non Currrent Assets Other
Non Current Liabilities Total	- 0.95	Total Stockholder Equity